LSD1 Inhibitor Combination Therapy for p21-Deficient Cancer Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies are inadequate for treating cancers that are resistant to available treatments, particularly those involving LSD1 inhibitors, due to reduced p21 expression or loss of p21 function in cancerous cells.
Innovation Solution
Administering a combination of cell cycle inhibitors, such as CDK4/6 inhibitors or p21 enhancers, alongside LSD1 inhibitors to sensitize LSD1-inhibitor-resistant cancer cells by enhancing p21 expression and promoting cell cycle arrest and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LSD1 inhibitors are administered alone, then cancer cell proliferation is inhibited, but resistant cancer cells with reduced p21 expression or loss of p21 function are not effectively treated
Solution Approach 1:
The patent combines LSD1 inhibitors with cell cycle inhibitors (CDK4/6 inhibitors or p21 enhancers) into a combination therapy regimen. This merging of two different therapeutic mechanisms addresses the resistance problem by targeting multiple pathways simultaneously - LSD1 inhibition for general anti-proliferative effects and cell cycle inhibition for overcoming p21-related resistance mechanisms, thereby restoring treatment effectiveness in resistant cancer cells
Solution Approach 2:
The patent changes the therapeutic parameter by introducing cell cycle inhibitors that specifically target the p21 pathway. This parameter change addresses the resistance mechanism (reduced p21 expression or loss of p21 function) by providing an alternative or complementary approach to overcome the resistance, thereby expanding the adaptability of the treatment to resistant cancer cells
2Reliability
If combination therapy with cell cycle inhibitors and LSD1 inhibitors is administered, then sensitivity of resistant cancer cells is improved, but treatment complexity increases
Solution Approach 1:
The patent merges two established drug classes (LSD1 inhibitors and cell cycle inhibitors) into a unified combination therapy. While this improves reliability by sensitizing resistant cells, it inherently increases treatment complexity. The patent manages this complexity by providing structured administration protocols and selecting from well-characterized agents in each class, making the combination therapy clinically implementable despite the increased complexity
Data Source
AI summary
Provided herein are compositions and methods of treating cancer with combinations of cell cycle inhibitors and LSD1 inhibitors. In some aspects, the cell cycle inhibitor is a CDK4/6 inhibitor, e.g., palbociclib. In some aspects, the LSD1 inhibitor is MC2580 or DDP38003. The compositions and methods of the disclosure may be used to treat cancers including, but not limited to, leukemia, lung cancer, melanoma, or breast cancer. The cancers may be, for example, LSD1-inhibitor-resistant and/or comprise cells having a reduced level of p21 expression or a loss of p21 function.